Last reviewed · How we verify
NCT03178955
Circadian RA Study in Rheumatoid Arthritis Subjects
trial testing Etanercept in Rheumatoid Arthritis. Withdrawn.
16 April 2019
Quick facts
| Lead sponsor | University of California, Davis |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 27 March 2017 |
| Primary completion | 16 April 2019 |
| Estimated completion | 16 August 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Etanercept (etanercept) — full drug profile →
Conditions studied
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Sponsor
University of California, Davis
Who can join
Adults 18 to 80, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary objective: To determine the changes in circadian activity rhythms and disease activity in rheumatoid arthritis (RA) patients from pre-treatment to one month after Enbrel initiation. Secondary objectives: * To determine if there is an association between changes in circadian rhythm and changes in disease activity in active RA after initiation of Enbrel * To determine if the changes in circadian activity rhythms are associated with systemic inflammation in RA patients * To determine changes in traditional sleep quality variables from pre-treatment to one month after Enbrel initiation in RA patients
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03178955
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Etanercept
Trials testing the same drug.
- NCT06016517 — Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis · not yet recruiting
- NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
- NCT06707194 — Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis · Phase 4 · recruiting
- NCT06011889 — Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome · Phase 2, PHASE3 · recruiting
- NCT05281614 — Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D · EARLY_PHASE1 · completed
Other recruiting trials for Rheumatoid Arthritis
Currently open trials in the same condition.
- NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
Other University of California, Davis trials
Trials by the same sponsor.
- NCT07024498 — Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment · NA · not yet recruiting
- NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) · Phase 4 · recruiting
- NCT07384767 — Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing · Phase 2 · not yet recruiting
- NCT07267494 — Image-Guided Herniorrhaphy Study · NA · not yet recruiting
- NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants · Phase 2, PHASE3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03178955 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
- Last refreshed: 14 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03178955.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing